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A B S T R A C T
Background
Hepatitis C virus (HCV) is a single-stranded RNA (ribonucleic acid) virus that has the potential to cause inflammation of the liver.
The traditional definition of acute HCV infection is the first six months following infection with the virus. Another commonly used
definition of acute HCV infection is the absence of HCV antibody and subsequent seroconversion (presence of HCV antibody in a
person who was previously negative for HCV antibody). Approximately 40% to 95% of people with acute HCV infection develop
chronic HCV infection, that is, have persistent HCV RNA in their blood. In 2010, an estimated 160 million people worldwide
(2% to 3% of the world’s population) had chronic HCV infection. The optimal pharmacological treatment of acute HCV remains
controversial. Chronic HCV infection can damage the liver.
Objectives
To assess the comparative benefits and harms of different pharmacological interventions in the treatment of acute HCV infection
through a network meta-analysis and to generate rankings of the available pharmacological treatments according to their safety and
efficacy.However, it was not possible to assess whether the potential effectmodifiers were similar across different comparisons. Therefore,
we did not perform the network meta-analysis, and instead, we assessed the comparative benefits and harms of different interventions
versus each other or versus no intervention using standard Cochrane methodology.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded,
World Health Organization International Clinical Trials Registry Platform, and randomised controlled trials registers to April 2016 to
identify randomised clinical trials on pharmacological interventions for acute HCV infection.
Selection criteria
We included only randomised clinical trials (irrespective of language, blinding, or publication status) in participants with acute HCV
infection. We excluded trials which included previously liver transplanted participants and those with other coexisting viral diseases.
We considered any of the various pharmacological interventions compared with placebo or each other.
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Data collection and analysis
We used standard methodological procedures expected by Cochrane. We calculated the odds ratio (OR) and rate ratio with 95%
confidence intervals (CI) using both fixed-effect and random-effects models based on the available-participant analysis with Review
Manager 5. We assessed risk of bias according to Cochrane, controlled risk of random errors with Trial Sequential Analysis, and assessed
the quality of the evidence using GRADE.
Main results
We identified 10 randomised clinical trials with 488 randomised participants thatmet our inclusion criteria. All the trials were at high risk
of bias in one or more domains. Overall, the evidence for all the outcomes was very low quality evidence. Nine trials (467 participants)
provided information for one or more outcomes. Three trials (99 participants) compared interferon-alpha versus no intervention. Three
trials (90 participants) compared interferon-beta versus no intervention. One trial (21 participants) compared pegylated interferon-
alpha versus no intervention, but it did not provide any data for analysis. One trial (41 participants) comparedMTH-68/B vaccine versus
no intervention. Two trials (237 participants) compared pegylated interferon-alpha versus pegylated interferon-alpha plus ribavirin.
None of the trials compared direct-acting antivirals versus placebo or other interventions. The mean or median follow-up period in
the trials ranged from six to 36 months.
There was no short-term mortality (less than one year) in any group in any trial except for one trial where one participant died in
the pegylated interferon-alpha plus ribavirin group (1/95: 1.1%). In the trials that reported follow-up beyond one year, there were no
further deaths. The number of serious adverse events was higher with pegylated interferon-alpha plus ribavirin than with pegylated
interferon-alpha (rate ratio 2.74, 95% CI 1.40 to 5.33; participants = 237; trials = 2; I2 = 0%). The proportion of people with any
adverse events was higher with interferon-alpha and interferon-beta compared with no intervention (OR 203.00, 95% CI 9.01 to
4574.81; participants = 33; trials = 1 and OR 27.88, 95% CI 1.48 to 526.12; participants = 40; trials = 1). None of the trials reported
health-related quality of life, liver transplantation, decompensated liver disease, cirrhosis, or hepatocellular carcinoma. The proportion
of people with chronic HCV infection as indicated by the lack of sustained virological response was lower in the interferon-alpha group
versus no intervention (OR 0.27, 95% CI 0.09 to 0.76; participants = 99; trials = 3; I2 = 0%). The differences between the groups
were imprecise or not estimable (because neither group had any events) for all the remaining comparisons.
Four of the 10 trials (40%) received financial or other assistance from pharmaceutical companies who would benefit from the findings
of the research; the source of funding was not available in five trials (50%), and one trial (10%) was funded by a hospital.
Authors’ conclusions
Very low quality evidence suggests that interferon-alpha may decrease the incidence of chronic HCV infection as measured by sus-
tained virological response. However, the clinical impact such as improvement in health-related quality of life, reduction in cirrhosis,
decompensated liver disease, and liver transplantation has not been reported. It is also not clear whether this finding is applicable in the
current clinical setting dominated by the use of pegylated interferons and direct-acting antivirals, although we found no evidence to
support that pegylated interferons or ribavirin or both are effective in people with acute HCV infection. We could find no randomised
trials comparing direct-acting antivirals with placebo or other interventions for acute HCV infection. There is significant uncertainty
in the benefits and harms of the interventions, and high-quality randomised clinical trials are required.
P L A I N L A N G U A G E S U M M A R Y
Medical treatment of acute hepatitis C virus infection
Background
Hepatitis C virus (HCV) is a virus that affects the liver. It is usually transmitted by injectable drug abuse, transfusion of infected blood,
unhygienic tattooing practices, coming into contact with blood infected with HCV, and unprotected sex. Acute HCV infection is the
period that covers within six months of infection. While some people clear the virus after acute HCV infection, the virus remains in
others. This is called chronic HCV infection and may cause major health problems such as excessive tiredness, and liver failure leading
to vomiting blood, confusion, and death. Overall, an estimated 160 million people worldwide (2% to 3% of the world’s population)
have chronic HCV infection. A number of medical treatments have been used for acute HCV infection. The best way to treat acute
HCV infection is not clear. We sought to resolve this issue by searching for existing studies on the topic. We included all randomised
clinical trials (clinical studies where people are randomly put into one of two or more intervention groups) whose results were reported
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to April 2016. We included only trials in which participants had not undergone liver transplantation previously and those who did
not have liver disease due to other viral infections. Apart from using standard Cochrane methods which allow comparison of only
two interventions at a time (direct comparison), we planned to use advanced method which allows comparison of the many different
interventions individually compared in the trials (network meta-analysis). However, because of the nature of the information available,
we could not determine whether the network meta-analysis results were reliable. So, we used standard Cochrane methodology.
Study characteristics
We identified 10 randomised clinical trials which were eligible for our review. Nine randomised clinical trials (467 participants)
provided information for one or more measures (outcomes). The main interventions compared included different forms of interferon
(protein secreted in response to viral infection), namely, interferon-alpha alone, interferon-beta alone, pegylated interferon-alpha alone,
pegylated interferon-alpha plus ribavirin (another antiviral drug), a vaccine called MTH-68/B made from a different virus, versus no
intervention. None of the trials compared direct-acting antivirals (the latest option for treating HCV infection) versus placebo or other
interventions. The average follow-up period in the trials ranged from six months to three years.
Source of funding
Four of the 10 trials (40%) received financial or other assistance from pharmaceutical companies who would benefit from the findings
of the research; the source of funding was not available in five trials (50%), and one trial (10%) was funded by a hospital.
Quality of evidence
All the trials were at high risk of bias, and the overall quality of the evidence was very low. This means that there is a possibility of
making wrong conclusions overestimating benefits or underestimating harms of one intervention or the other because of the way that
the trials were conducted.
Key results
No deaths occurred less than one year after treatment in any group in any trial except for one trial where one participant died in the
pegylated interferon-alpha plus ribavirin group (1/95: 1.1%). In the trials in which participants were followed up beyond one year,
there were no further deaths. The number of serious complications was higher with pegylated interferon-alpha plus ribavirin than with
pegylated interferon-alpha. The percentage of people with any complications was higher with interferon-alpha and interferon-beta than
with no intervention. None of the trials reported health-related quality of life, liver transplantation, liver failure, severe liver damage,
or liver cancer. The percentage of people in whom the virus remained in the blood six months after the end of treatment was lower in
the interferon-alpha than in the no intervention groups. There was no evidence of differences between the groups for all the remaining
comparisons. There is significant uncertainty about the size and direction of the results and high quality randomised clinical trials are
required.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Intervention versus no intervention or control intervention (control) for acute hepatitis C infection: primary outcomes
Patient or population: people with acute hepat it is C infect ion
Intervention: mult iple
Control: mult iple
Settings: secondary or tert iary care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Intervention
M ortality: there was 1 mortality within 6 months (in the pegylated interferon-alpha group (1/ 95 = 1.1%). There was no mortality in the remaining groups. There was no further
mortality in the trials which reported mortality unt il maximal follow-up
Serious adverse events: there were no serious adverse events in either group in the comparisons interferon-beta versus control and MH-68/ B vaccine versus control. Trials in
interferon-alpha versus control did not report serious adverse events
Serious adverse events
(proportion) - pegylated
interferon-alpha plus rib-
avirin versus pegylated in-
terferon-alpha
70 per 1000 115 per 1000
(50 to 242)
OR 1.72
(0.7 to 4.21)
237
(2 RCTs)
⊕©©©
Very low1,2,3
Serious adverse events
(number) - pegylated in-
terferon-alpha plus rib-
avirin versus pegylated in-
terferon-alpha
92 per 1000 251 per 1000
(128 to 488)
Rate ratio 2.74
(1.40 to 5.33)
237
(2 RCTs)
⊕©©©
Very low1,2
Adverse events (propor-
tion) - interferon-alpha ver-
sus no intervention
10 per 1000 672 per 1000
(83 to 979)
OR 203
(9.01 to 4574.81)
33
(1 RCT)
⊕©©©
Very low1,2
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Adverse events (propor-
tion) - interferon-beta ver-
sus no intervention
10 per 1000 220 per 1000
(15 to 842)
OR 27.88
(1.48 to 526.12)
40
(1 RCT)
⊕©©©
Very low1,2
Adverse events: there were no adverse events in the comparison MTH-68/ B vaccine versus control. The number of adverse events was not reported for the comparison
interferon-alpha versus control. The proport ion of people with adverse events and number of adverse events was not reported for the comparison pegylated interferon-alpha
plus ribavirin versus pegylated interferon-alpha
Adverse events (number) -
interferon-beta versus no
intervention
10 per 1000 147 per 1000
(10 to 748)
OR 17
(0.98 to 294.53)
40
(1 RCT)
⊕©©©
Very low1,2,3
Health- related quality of
life
None of the trials reported this outcome.
None of the trials reported health-related quality of lif e, cirrhosis, decompensated liver disease, liver transplantat ion, or hepatocellular carcinoma
* The basis for the assumed risk is the mean control group proport ion (or control group rate) unless there were no events in the control group when the control group proport ion
(or control group rate) was considered as 1%. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised clinical trial.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded 2 levels for high risk of bias.
2 Downgraded 1 level for small sample size (i.e. imprecision).
3 Downgraded 1 level for wide conf idence intervals (i.e. imprecision).
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B A C K G R O U N D
Description of the condition
Hepatitis C virus (HCV) is a single-stranded RNA (ribonucleic
acid) virus that has the potential to cause inflammation of the
liver (NCBI 2014a). There is some variation in the RNA se-
quence of HCV and currently, seven genotypes (genotypes 1 to
7) are recognised (Smith 2014). The major mode of transmis-
sion of HCV is by parenteral routes, which includes parenteral
drug abuse, transfusion of infected blood, unhygienic tattooing
practices, and occupational exposure to the blood of HCV-in-
fected people (Beltrami 2000; Xia 2008; Kleinman 2009; Jafari
2010; Loomba 2011; Bunchorntavakul 2015). The other modes
of transmission include sexual intercoursewith infected people and
perinatal transmission from mother to child (Syriopoulou 2005;
Tohme 2010). Acute HCV infection is defined in different ways
(Hajarizadeh 2012). The traditional definition of acute HCV in-
fection is the first six months following exposure to viral infection
(Grebely 2011). However, as most people are asymptomatic after
acute HCV infection (Kamal 2008; Grebely 2011), it is difficult
to identify the exact duration of infection (Hajarizadeh 2012).
The absence of the HCV antibody and subsequent seroconver-
sion (presence of HCV antibody in a person who was previously
negative for HCV antibody) is the most common definition used
in studies related to acute HCV infection (Hajarizadeh 2012).
Other criteria that have been used to assess treatment effects in-
clude alanine transaminase elevation and HCV RNA detection
(Hajarizadeh 2012). Presence of HCV RNA in the absence of
HCV antibody in the serum and subsequent seroconversion accu-
rately diagnoses very recent acute HCV infection, but it is uncom-
mon in clinical practice (Hajarizadeh 2012). While HCV RNA
can be detected in the circulation about one to two weeks after
exposure to infection, seroconversion may be evident only two to
six months after the exposure to infection (Kamal 2008).
Approximately 10% to 30% of people with acute HCV de-
velop symptoms (Kamal 2008; Maheshwari 2008). The symp-
toms and signs related to acute HCV infection include jaundice,
fatigue, muscle pain, influenza-like illness, low-grade fever, nau-
sea, vomiting, and right upper abdominal pain (Kamal 2008;
Maheshwari 2008). Acute HCV is rarely fulminant (Kamal
2008; Maheshwari 2008). Symptoms usually occur within six
to eight weeks after exposure and last for about three to 12
weeks (Kamal 2008). Approximately 40% to 95% of people
with acute HCV infection develop chronic HCV infection, that
is, have persistent HCV RNA in their blood (Lehmann 2004;
Wawrzynowicz-Syczewska 2004; Kamal 2008; Maheshwari 2008;
Beinhardt 2012; Bunchorntavakul 2015), depending upon the
genotype of the HCV (Lehmann 2004). Various factors that can
predict the development of chronic HCV infection have been
proposed but none are sufficiently reliable to guide management
(Maheshwari 2008; EASL 2014). Presence of jaundice, HCV
genotypes 1 and 3, favourable interleukin-28B genotype, female
sex, being white by ethnic origin, having a low peak viral load,
and having a rapid decline in viral load within the first four weeks
of diagnosis are all associated with spontaneous clearance of the
HCV infection (Maheshwari 2008; Grebely 2014). However, be-
ing of Afro-Caribbean ethnic origin and having a coexistent HIV
infection is associated with increased risk of chronic HCV infec-
tion (Maheshwari 2008).
Chronic HCV infection is a slowly progressive disease. Approx-
imately 1% to 39% of people who develop chronic HCV infec-
tion develop liver cirrhosis (advanced liver fibrosis) after a pe-
riod of seven to 30 years due to damage to the liver by HCV
(Poynard 1997; Kenny-Walsh 1999; Rodger 2000; Wiese 2005;
Seeff 2009). Cirrhosis has two phases, an asymptomatic ’com-
pensated cirrhosis’ phase and a ’decompensated cirrhosis’ phase,
characterised by clinical symptoms such as upper gastrointestinal
bleeding from varices, ascites, encephalopathy, jaundice, or renal
failure (D’Amico 2006). Liver-related complications such as cir-
rhosis, hepatocellular carcinoma, decompensated liver disease, and
mortality usually occur 15 to 20 years after the initial infection in a
proportion of people (Wiese 2005). Every year, 1% to 4% of peo-
ple referred to the hospital with HCV-related cirrhosis die (4%);
develop liver failure manifested as ascites (3%); or develop jaun-
dice (2%), gastrointestinal bleeding (1%), or hepatocellular carci-
noma (4%) (Sangiovanni 2006). The median survival after com-
pensated liver disease is more than 10 years while that of decom-
pensated liver disease is less than two years (D’Amico 2006). The
only definitive treatment for decompensated liver cirrhosis is liver
transplantation. The median survival after liver transplantation
for chronic HCV infection is between six and eight years (Uemura
2012; Singal 2013). There is also improvement in the quality of
life of people with chronic liver disease after liver transplantation
(Yang 2014). In 2010, an estimated 160 million people worldwide
(2% to 3% of the world’s population) had chronic HCV infec-
tion (Lavanchy 2011). There is a global variation in the prevalence
of chronic HCV infection with highest prevalence in Africa and
the Eastern Mediterranean region (Global Burden of Hepatitis C
Working Group 2004). In 2010, on average, approximately USD
400 were spent on each person each year with chronic HCV infec-
tion without complications (El Khoury 2012). Once people de-
velop complications, the healthcare costs increase exponentially.
The annual healthcare costs associated with compensated HCV
cirrhosis are USD 1080 per person; annual healthcare costs asso-
ciated with decompensated HCV cirrhosis are USD 17,070 per
person; and annual healthcare costs associated with liver trans-
plantation associated with HCV cirrhosis are USD 146,960 per
person (El Khoury 2012).
Description of the intervention
Various drugs such as interferon, direct-acting antivirals (rib-
avirin; protease inhibitors such as telaprevir), or a combination
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of these have been used with the aim of eradicating acute HCV
infection, thereby preventing progression to chronic HCV infec-
tion and subsequent complications related to chronic HCV in-
fection (Maheshwari 2008; Grebely 2011; Fierer 2014). Inter-
ferons are proteins secreted by cells in response to a wide range
of inducers that confer resistance against viruses and cancer cells
(NCBI 2014b). The major types of interferon include interferon-
alpha, interferon-beta, interferon-omega, interferon-lambda, and
interferon-gamma (Feld 2005; NCBI 2014b). Interferon-alpha is
the most common interferon used to treat acute HCV infection
(Myers 2001; Maheshwari 2008; Grebely 2011), and interferon-
beta has also been evaluated (Myers 2001). Interferon is usually
manufactured by recombinant technology where a sequence of
human DNA is combined with the DNA of bacteria such as Es-
cherichia coli so that large-scale quantities of interferon are pro-
duced by Escherichia coli (Anonymous 1981). A variation of in-
terferon-alpha is pegylated interferon-alpha where the structure
of interferon is modified to make it long acting (Bailon 2001).
Interferon-alpha is usually administered by subcutaneous or intra-
muscular injections (Martindale 2011). Ribavirin is a guanosine
analogue (Feld 2005). It is usually administered orally (Martindale
2011). Telaprevir, boceprevir, danoprevir, and ABT-450 are called
direct-acting antiviral agents as they inhibit viral proteins (Lewis
2012; Welsch 2012; Poordad 2014). Of these, telaprevir and bo-
ceprevir are first-generation direct-acting antiviral agents as these
were the first direct-acting antiviral agents licensed for use in
chronic HCV infections (Lewis 2012). The remaining antiviral
agents are second-generation direct-acting antiviral agents (Lewis
2012). The direct-acting antiviral agents are usually administered
orally (Martindale 2011). It should be noted that these treatments
have significant complications including mortality, severe infec-
tions, severe liver decompensation, refractory anaemia, neutrope-
nia, thrombocytopenia, and neuropsychiatric disorders (homici-
dal and suicidal ideation) with different treatments having differ-
ent safety profiles (Martindale 2011; Perry 2012; Furusyo 2013;
Hezode 2013; Coilly 2014).
How the intervention might work
Interferon is one of the natural defence mechanisms of the body
against viruses (Feld 2005; NCBI 2014b). Interferons induce in-
terferon-stimulated genes, which creates an antiviral state within
the cells (Feld 2005). Ribavirin may act by inhibiting the HCV
RNA polymerase (which plays a significant role in viral replica-
tion), inducing mutations in the virus and making them less in-
fective, and by modifying the immune response (immunomodu-
lation), which promotes clearance of virus from cells (Feld 2005).
Direct-acting antiviral agents inhibit viral proteins involved in the
HCV life cycle and so inhibit replication of the virus (Welsch
2012).
Why it is important to do this review
There is significant controversy as to whether any intervention is
beneficial in acute HCV infection. Currently, the European Asso-
ciation for the Study of the Liver (EASL) and the American Associ-
ation for the Study of LiverDiseases (AASLD) have no recommen-
dations for treatment directed at acute HCV infection (AASLD
2014; EASL 2014). However, some investigators recommend pe-
gylated interferon for people with acute HCV infection, usually
started three months after diagnosis after repeat serum testing to
allow threemonths for spontaneous resolution (Maheshwari 2008;
Grebely 2011). Thus, the treatment of acute HCV is controver-
sial. In addition, several treatment combinations are available for
the treatment of acute HCV infection, and the relative ranking of
different treatments in terms of clinical effectiveness and harms is
unknown.
Network meta-analysis allows combination of the direct evidence
and indirect evidence, and allows ranking of different treatments
in terms of the different outcomes (Salanti 2011; Salanti 2012).
There has been no network meta-analysis on this topic although
there has been one head-to-head comparison Cochrane systematic
review comparing interferon versus placebo or no intervention in
people with acute HCV infection (Myers 2001). The present sys-
tematic review and attempted network meta-analysis intended to
provide the best level of evidence for the role of different phar-
macological interventions in the treatment of people with acute
HCV infection.
O B J E C T I V E S
To assess the comparative benefits and harms of different pharma-
cological interventions in the treatment of acute HCV infection
through a network meta-analysis and to generate rankings of the
available pharmacological treatments according to their safety and
efficacy. However, it was not possible to assess whether the po-
tential effect modifiers were similar across different comparisons.
Therefore, we did not perform the network meta-analysis, and in-
stead, we assessed the comparative benefits and harms of different
interventions versus each other or versus no intervention using
standard Cochrane methodology.
When more trials become available with adequate description of
potential effect modifiers, we will attempt to conduct network
meta-analysis to generate rankings of the available treatments ac-
cording to their safety and efficacy. This iswhywe have retained the
planned methodology for network meta-analysis in our Appendix
1. Once data appear allowing for the conduct of network meta-
analysis, this Appendix 1 will be moved back into the Methods
section.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We considered only randomised clinical trials for themeta-analysis
irrespective of language, publication status, or date of publication.
We excluded studies of other design because of the risk of bias in
such studies. We are all aware that such exclusions make us focus
much more on potential benefits and not fully assess the risks of
serious adverse events as well as risks of adverse events.
Types of participants
We included randomised clinical trialswith participantswith acute
HCV infection (absence of HCV antibody and subsequent sero-
conversion (presence of HCV antibody in a person who was previ-
ously negative for HCV antibody or less than six months of HCV
infection)), irrespective of the method of diagnosis of seroconver-
sion or HCV genotype. We excluded randomised clinical trials in
which participants had undergone liver transplantation previously.
We also excluded randomised clinical trials in which participants
had other coexisting viral diseases such as HIV or hepatitis B virus
coinfections.
Types of interventions
We included any of the following pharmacological interventions
that are possible treatments for acute HCV infection, either alone
or in combination and could be compared versus each other or
versus placebo or no intervention.
The interventions that we considered a priori were:
• interferon-alpha;
• pegylated interferon-alpha;
• interferon-beta;
• ribavirin;
• first-generation direct-acting antiviral agents (boceprevir
and telaprevir);
• second-generation direct-acting antiviral agents (other
direct-acting antiviral agents).
The above list of interventions was not an exhaustive list. If we
identified any other pharmacological interventions that we were
not aware of (e.g. we included MTH-68/B), we considered them
eligible and included them in the review if theywere used primarily
for the treatment of acute HCV infection.
Types of outcome measures
We planned to assess the comparative benefits and harms of avail-
able pharmacological interventions aimed at treating people with
acute HCV infection for the following outcomes.
Primary outcomes
• Mortality at maximal follow-up (time to death).
• Mortality:
◦ short-term mortality (up to one year);
◦ medium-term mortality (one to five years).
• Adverse events (within three months of cessation of
treatment). We extracted adverse events and serious adverse
events as reported in the studies. In general, we defined a non-
serious adverse event as any untoward medical occurrence not
necessarily having a causal relationship with the treatment but
resulting in a dose reduction or discontinuation of treatment
(any time after commencement of treatment) (ICH-GCP 1997),
and defined a serious adverse event as any event that would
increase mortality; was life threatening; required hospitalisation;
resulted in persistent or significant disability; was a congenital
anomaly/birth defect; or any important medical event that might
jeopardise the person or require intervention to prevent it.
◦ Proportion of participants with serious adverse events.
◦ Number of serious adverse events.
◦ Proportion of participants with any type of adverse
event.
◦ Number of any type of adverse event.
• Health-related quality of life as defined in the included
trials using a validated scale such as EQ-5D or 36-item Short
Form (SF-36) (EuroQol 2014; Ware 2014):
◦ short-term (up to one year);
◦ medium-term (one to five years);
◦ long-term (beyond five years).
We planned to consider short-term quality of life to be more im-
portant than medium-term or long-term quality of life, although
medium-term and long-term quality of life are also important pri-
mary outcomes.
Secondary outcomes
• Liver transplantation (maximal follow-up):
◦ proportion of participants with liver transplantation;
◦ time to liver transplantation.
• Decompensated liver disease (presence of one or more of
bleeding varices, ascites, encephalopathy, jaundice) (maximal
follow-up):
◦ proportion of participants with decompensated liver
disease;
◦ time to liver decompensation.
• Cirrhosis (scarring of the liver caused by continuous, long-
term liver damage or stage IV fibrosis) (maximal follow-up):
◦ proportion of participants with cirrhosis;
◦ time to cirrhosis.
• Proportion of participants with hepatocellular carcinoma
(maximal follow-up).
• Proportion of participants with chronic HCV infection
(however defined by trial authors).
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Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, and Science Citation Index
Expanded (which includes Conference Proceedings) (Royle 2003)
from inception to 16 April 2016 for randomised clinical trials
comparing twoormore of the above interventions.We searched for
all possible comparisons formedby the interventions of interest. To
identify further ongoing or completed trials, we also searched the
World Health Organization International Clinical Trials Registry
Platform Search Portal (apps.who.int/trialsearch/), which searches
various trial registers, including ISRCTN and ClinicalTrials.gov
on 16 April 2016. Appendix 2 shows the search strategies we used.
Searching other resources
We searched the references of the identified trials and the existing
Cochrane Reviews on acute HCV infection to identify additional
trials for inclusion.
Data collection and analysis
Selection of studies
Two review authors (MK and EB) independently identified the
trials for inclusion by screening the titles and abstracts. We sought
full-text articles for any references that at least one of the review
authors identified for potential inclusion. We selected the trials
for inclusion based on the full-text articles. We planned to list
the excluded full-text references with reasons for their exclusion
in the Characteristics of excluded studies table. We also planned
to list any ongoing trials identified primarily through the search
of the clinical trial registers for further follow-up. We resolved
discrepancies through discussion and by arbitration with KG, DT,
and ET.
Data extraction and management
Two review authors (MK and EB) independently extracted the
following data.
• Outcome data (for each outcome and for each treatment
arm whenever applicable):
◦ number of participants randomised;
◦ number of participants included for the analysis;
◦ number of participants with events for binary
outcomes, mean and standard deviation for continuous
outcomes, number of events for count outcomes, and the
number of participants with events and the mean follow-up
period for time-to-event outcomes;
◦ definition of outcomes or scale used if appropriate.
• Data on potential effect modifiers:
◦ participant characteristics such as age, sex,
comorbidities, proportion of participants with different HCV
genotypes, and severity of acute HCV infection, however defined
by trial authors;
◦ details of the intervention and control (including dose,
frequency, and duration);
◦ risk of bias (assessment of risk of bias in included
studies).
• Other data:
◦ year and language of publication;
◦ country in which the participants were recruited;
◦ year(s) in which the trial was conducted;
◦ inclusion and exclusion criteria;
◦ follow-up time points of the outcome.
If available, we planned to obtain the data separately for different
genotypes from the report. We sought unclear or missing infor-
mation by attempting to contact the trial authors. If there was any
doubt whether trials shared the same participants, completely or
partially (by identifying commonauthors and centres), we planned
to contact the trial authors to clarify whether the trial report was
duplicated. We resolved any differences in opinion through dis-
cussion.
Assessment of risk of bias in included studies
We followed the guidance given in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011) and in the
Cochrane Hepato-Biliary Module (Gluud 2015) to assess the risk
of bias in included studies. Specifically, we assessed the risk of bias
in included trials for the following domains, using the methods
below (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008;
Savovi 2012a; Savovi 2012b; Lundh 2017).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were adequate if an independent person
not otherwise involved in the study performed them.
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The investigators were unaware of the allocation sequence (e.g. if
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the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so the intervention
allocations may have been foreseen before, or during, enrolment.
• High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence.
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but we judged that the outcome was not
likely to be influenced by lack of blinding; or blinding of
participants and key study personnel ensured, and it was unlikely
that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome was likely to be
influenced by lack of blinding; or blinding of key study
participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome was likely to
be influenced by lack of blinding.
Blinding of outcome assessors
• Low risk of bias: any of the following: no blinding of
outcome assessment, but we judged that the outcome
measurement was not likely to be influenced by lack of blinding;
or blinding of outcome assessment ensured, and unlikely that the
blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement was likely
to be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement was likely to be influenced by
lack of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined
outcomes: long-term outcomes related to the disease process
(namely, mortality or decompensated liver disease, or
requirement for transplantation along with treatment-related
adverse events). If the original trial protocol was available, the
outcomes should have been those called for in that protocol. If
the trial protocol was obtained from a trial registry (e.g.
www.clinicaltrials.gov), the outcomes sought should have been
those enumerated in the original protocol if the trial protocol
was registered before or at the time that the trial was begun. If
the trial protocol was registered after the trial was begun, those
outcomes were not considered to be reliable.
• Unclear risk of bias: not all predefined outcomes were
reported fully, or it was unclear whether data on these outcomes
were recorded or not.
• High risk of bias: one or more predefined outcomes were
not reported.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that may
manipulate the trial design, conductance, or results of the trial.
• Unclear risk of bias: the trial may or may not have been free
of for-profit bias as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
components (e.g. inappropriate control or dose or
administration of control) that could put it at risk of bias.
• Unclear risk of bias: the trial may or may not have been free
of other components that could have put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could have put it at risk of bias (e.g. inappropriate control or
dose or administration of control).
We considered a trial at low risk of bias if we assessed the trial as
at low risk of bias across all domains. Otherwise, we considered
the trials at high risk of bias regarding one or more domains as at
high risk of bias.
Measures of treatment effect
For dichotomous variables (e.g. short-term and medium-term
mortality or liver transplantation, proportion of participants with
adverse events, decompensated liver disease, cirrhosis, hepatocel-
lular carcinoma, or sustained virological response), we calculated
the odds ratio (OR) with 95% confidence intervals (CI). For con-
tinuous variables (e.g. quality of life reported on the same scale),
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we planned to calculate the mean difference with 95% CI. We
planned to use standardised mean difference values with 95% CI
for quality of life if included trials used different scales. For count
outcomes (e.g. number of adverse events), we calculated the rate
ratio with 95% CI. For time-to-event data (e.g. mortality at max-
imal follow-up or requirement for liver transplantation, time to
liver decompensation, and time to cirrhosis), we planned to use
the hazard ratio (HR) with 95% CIs. We also calculated Trial Se-
quential Analysis-adjusted CI to control random errors (Thorlund
2011).
Unit of analysis issues
The unit of analysis was people with acute HCV infection ac-
cording to the intervention group to which they were randomly
assigned.
Cluster randomised clinical trials
As expected, we found no cluster randomised clinical trials. If we
had found them, we planned to include them provided that the
effect estimate adjusted for cluster correlation was available.
Cross-over randomised clinical trials
As expected, we found no cross-over randomised clinical trials. If
we had identified any, we planned to only include the outcomes
after the period of first treatment because acute HCV infection
may resolve before the cross-over period.
Trials with multiple intervention groups
We collected data for all trial intervention groups that met the
inclusion criteria.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992). Otherwise, we used the data that were available
to us (e.g. a trial might have reported only per-protocol analysis
results). As such ’per-protocol’ analyses may be biased, we planned
to conduct best-worst case scenario analyses (good outcome in
intervention group and bad outcome in control group) and worst-
best case scenario analyses (bad outcome in intervention group and
good outcome in control group) as sensitivity analyses whenever
possible but because of lack of the required information for such
analyses, we did not perform them.
For continuous outcomes, we planned to impute the standard de-
viation from P values according to guidance given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011). If
the data were likely to be normally distributed, we planned to use
the median for meta-analysis when the mean was not available. If
it was not possible to calculate the standard deviation from the P
value or the CIs, we planned to impute the standard deviation us-
ing the largest standard deviation in other trials for that outcome.
This form of imputation may decrease the weight of the study for
calculation of mean differences and may bias the effect estimate to
no effect for calculation of standardised mean differences (Higgins
2011).
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by care-
fully examining the characteristics and design of included trials.
We planned to assess the presence of clinical heterogeneity by
comparing effect estimates in the different HCV genotypes and
the different regimens (e.g. different agents, different doses, and
different durations) of the pharmacological treatments. Different
study designs and risk of bias may contribute to methodological
heterogeneity. We used the I2 test and Chi2 test for heterogeneity,
and overlapping of CIs to assess heterogeneity.
Assessment of reporting biases
We planned to use visual asymmetry on a funnel plot to explore
reporting bias in the presence of at least 10 trials that could be
included for a direct comparison (Egger 1997;Macaskill 2001). In
the presence of heterogeneity that could be explained by subgroup
analysis, we planned to produce a funnel plot for each subgroup
in the presence of an adequate number of trials. We planned to
use the linear regression approach described by Egger 1997 to
determine funnel plot asymmetry.
We also considered selective reporting as evidence of reporting
bias.
Data synthesis
We performed the meta-analyses according to Cochrane recom-
mendations (Higgins 2011), using the software package Review
Manager 5 (RevMan 2014). We used a random-effects model
(DerSimonian 1986) and a fixed-effect model (Demets 1987). In
the case of a discrepancy between the two models, we have re-
ported both results; otherwise, we reported only the results from
the fixed-effect model.
Calculation of required information size and Trial Sequential
Analysis
For calculation of the required information size, see Appendix 3.
We performed Trial Sequential Analysis to control the risks of
random errors when there were at least two trials included in the
meta-analysis (Wetterslev 2008; Thorlund 2011; TSA 2011). We
used an alpha error as per guidance of Jakobsen 2014, power of
90% (beta error of 10%), a relative risk reduction of 20%, a control
group proportion observed in the trials, and the diversity observed
in the meta-analysis.
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Subgroup analysis and investigation of heterogeneity
Weplanned to assess the differences in the effect estimates between
the following subgroups.
• Trials with low risk of bias compared to trials with high risk
of bias.
• Different HCV genotypes.
• Different regimens of pharmacological treatments. For
example, boceprevir compared to telaprevir, different doses, and
different durations.
However, we could not conduct these subgroup analyses.
Weplanned touse theChi2 test for subgroupdifferences to identify
subgroup differences.
Sensitivity analysis
If a trial reported only per-protocol analysis results, we planned
to re-analyse the results using the best-worst case scenario and
worst-best case scenario analyses as sensitivity analyses whenever
possible. However, we did not perform these analyses because of
insufficient information in the trials.
Presentation of results and GRADE assessments
We reported all outcomes in a ’Summary of findings’ table format,
downgrading the quality of evidence for risk of bias, inconsistency,
indirectness, imprecision, and publication bias using GRADE (
Guyatt 2011).
R E S U L T S
Description of studies
Results of the search
We identified 2803 references through electronic searches ofCEN-
TRAL (n = 257), MEDLINE (n = 1681), Embase (n = 323), Sci-
ence Citation Index Expanded (n = 514), World Health Orga-
nization International Clinical Trials Registry Platform (n = 8),
and randomised controlled trials registers (n = 20). After the re-
moval of 720 duplicates, we obtained 2083 references. We then
excluded 2070 clearly irrelevant references through screening ti-
tles and reading abstracts. We retrieved 13 references for further
assessment. No references were identified through scanning ref-
erence lists of the identified randomised trials. We included all
13 references (10 trials) that met the inclusion criteria (Omata
1991; Genesca 1993; Hwang 1994; Lampertico 1994; Omata
1994; Calleri 1998; Csatary 1998; Wang 2005; Deterding 2013;
Santantonio 2014). The reference flow is summarised in the study
flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
The 10 randomised clinical trials included 488 participants
(Omata 1991; Genesca 1993; Hwang 1994; Lampertico 1994;
Omata 1994; Calleri 1998; Csatary 1998; Wang 2005; Deterding
2013; Santantonio 2014). Nine trials (467 participants) provided
information for one or more outcomes (Omata 1991; Genesca
1993;Hwang 1994; Lampertico 1994;Omata 1994;Calleri 1998;
Csatary 1998;Deterding 2013; Santantonio 2014).One trial was a
three-armed trial which compared two different doses of pegylated
interferon versus pegylated interferon plus ribavirin (Santantonio
2014). The remaining nine trials were two-armed trials (Omata
1991; Genesca 1993; Hwang 1994; Lampertico 1994; Omata
1994; Calleri 1998; Csatary 1998; Wang 2005; Deterding 2013).
Table 1 summarises the details of the intervention, control, the
period of follow-up, and the risk of bias in the trials arranged ac-
cording to intervention and control. Three trials (99 participants)
compared interferon-alpha versus no intervention (Genesca 1993;
Hwang 1994; Lampertico 1994). Three trials (90 participants)
compared interferon-beta versus no intervention (Omata 1991;
Omata 1994; Calleri 1998). One trial (41 participants) compared
MTH-68/B vaccine versus no intervention (Csatary 1998). One
trial (21 participants) compared pegylated interferon-alpha versus
no intervention, but it did not provide any data for the analy-
sis (Wang 2005). Two trials (237 participants) compared pegy-
lated interferon-alpha versus pegylated interferon-alpha plus rib-
avirin (Deterding 2013; Santantonio 2014). None of the trials
compared direct-acting antivirals versus other interventions. The
mean or median follow-up period in the trials ranged from six to
36 months.
Themeanormedian age in the trials that reported this information
ranged from 29 to 54 years. The proportion of females in the
trials that reported this information ranged from 15% to 56%.
Three trials reported the proportion of participants with HCV
genotype 1, which were 61.9% (Wang 2005); 68.2% (Deterding
2013); and 61.6% (Santantonio 2014). Two trials reported the
proportion of participants with genotype 3, which were 16.8%
(Deterding 2013); and 37,2% (Santantonio 2014). None of the
trials provided information separately for the different genotypes.
Source of funding: four trials received financial or other assis-
tance from pharmaceutical companies who would benefit from
the findings of the research (Hwang 1994; Lampertico 1994;
Deterding 2013; Santantonio 2014); one trial was funded by a
hospital (Calleri 1998); the source of funding was not available in
the remaining trials (Omata 1991; Genesca 1993; Omata 1994;
Csatary 1998; Wang 2005).
Risk of bias in included studies
The risk of bias in the included trials is summarised in Figure 2
and Figure 3. The trials were at high risk of bias in one or more
domains, so all trials were assessed at overall high risk of bias.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Six trials were at low risk of random sequence generation bias
(Omata 1991; Hwang 1994; Lampertico 1994; Calleri 1998;
Deterding 2013; Santantonio 2014). One trial was at low risk of
allocation concealment bias (Omata 1991).
Blinding
None of the trials reported blinding of participants and healthcare
providers. One trial was at low risk of bias due to blinding of
outcome assessors (Deterding 2013).
Incomplete outcome data
Six trials were at low risk of attrition bias (Genesca 1993; Omata
1994; Calleri 1998; Csatary 1998; Deterding 2013; Santantonio
2014).
Selective reporting
Four trials were at low risk of selecting outcome reporting bias
(Hwang 1994; Calleri 1998; Csatary 1998; Deterding 2013).
Other potential sources of bias
One trial was at low risk of for-profit bias (Calleri 1998). All the
trials were at low risk of other bias.
Effects of interventions
See: Summary of findings for the main comparison
Intervention versus no intervention or control intervention
(control) for acute hepatitis C infection: primary outcomes;
Summary of findings 2 Intervention versus no intervention or
control intervention (control) for acute hepatitis C infection:
secondary outcomes
Mortality
Mortality at maximal follow-up
Eight trials (337 participants) reported mortality at maximal fol-
low-up (Omata 1991; Genesca 1993; Hwang 1994; Lampertico
1994;Omata 1994; Calleri 1998; Csatary 1998;Deterding 2013).
The period of follow-up ranged from six to 36 months. There
were no deaths reported in any of these trials.
Short-term mortality
Nine trials reported short-term mortality (less than one year)
(Omata 1991; Genesca 1993; Hwang 1994; Lampertico 1994;
Omata 1994; Calleri 1998; Csatary 1998; Deterding 2013;
Santantonio 2014). There was no short-term mortality in any
group in any trial except for one trial where one participant died
(Santantonio 2014). The unadjusted rates of mortality (short-
term) were 0% in all intervention groups except pegylated inter-
feron-alpha plus ribavirin in which the mortality was 1.1% (1/95
participants).
Medium-term mortality
Three trials (90 participants) reported medium-term mortality
(one to five years) (Omata 1991; Omata 1994; Calleri 1998).
All three trials compared interferon-beta versus no intervention.
There was no mortality in either group after a follow-up of two to
three years.
Adverse events
Proportion of people with serious adverse events
Four trials (318 participants) reported the proportion of people
with serious adverse events (Calleri 1998;Csatary 1998;Deterding
2013; Santantonio 2014). In two trials (one comparing interferon-
beta versus no intervention (Calleri 1998) and one comparing
MTH-68/B vaccine versus no intervention (Csatary 1998)), there
were no serious adverse events in either group. In the remaining
two trials, the proportion of people with serious adverse events in
the pegylated interferon-alpha plus ribavirin group was adjusted
proportion: 11.5% and in pegylated interferon-alpha group was
10/142 (7.0%). There was no evidence of difference between pe-
gylated interferon-alpha plus ribavirin versus pegylated interferon-
alpha (OR 1.72, 95% CI 0.70 to 4.21; participants = 237; trials
= 2; I2 = 0%; Analysis 1.1).
Number of serious adverse events
Four trials (318 participants) reported the number of people with
serious adverse events (Calleri 1998; Csatary 1998; Deterding
2013; Santantonio 2014). In two trials (one comparing interferon-
beta versus no intervention (Calleri 1998) and one comparing
MTH-68/B vaccine versus no intervention (Csatary 1998)), there
were no serious adverse events in either group. In the remaining
two trials, the rates for number of serious adverse events in the
pegylated interferon-alpha plus ribavirin group were 25.1 per 100
participants and in the pegylated interferon-alpha group were 9.2
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per 100 participants. The number of serious adverse events was
significantly higher with pegylated interferon-alpha plus ribavirin
thanwith pegylated interferon-alpha interventions (rate ratio 2.74,
95% CI 1.40 to 5.33; participants = 237; trials = 2; I2 = 0%;
Analysis 1.2).
Proportion of people with any type of adverse events
Three trials (114 participants) reported the proportion of people
with any adverse events (Hwang 1994; Calleri 1998; Csatary
1998). There were no adverse events in people receivingMTH-68/
B vaccine versus no intervention. The proportions of people with
adverse events in the interferon-alpha group was 87.5% (14/16)
and in the interferon-beta groupwas 40%(8/20).Compared to the
no intervention group the proportion of people with any adverse
events was higher in the interferon-alpha and the interferon-beta
group (interferon-alpha: OR 203.00, 95% CI 9.01 to 4574.81;
participants = 33; trials = 1; interferon-beta: OR 27.88, 95% CI
1.48 to 526.12; participants = 40; trials = 1; Analysis 1.3). The
difference in the proportion of people with adverse events was not
estimable in the comparison between MTH-68/B vaccine versus
no intervention group as there were no adverse events in either
group.
Number of any type of adverse events
Two trials (81 participants) reported number of adverse events
(Calleri 1998; Csatary 1998). There were no adverse events in the
MTH-68/B vaccine or no intervention groups. There were eight
adverse events reported in 20 participants in the interferon-beta
group (adverse event rate: 14.7 per 100 participants). There was no
statistically significant difference in the number of adverse events
between the interferon-beta group and the no intervention group
(OR 17.00, 95% CI 0.98 to 294.53; participants = 40; trials = 1;
Analysis 1.4).
Health-related quality of life
None of the trials reported health-related quality of life at any time
point.
Liver transplantation
None of the trials reported liver transplantation.
Decompensated liver disease
None of the trials reported decompensated liver disease.
Cirrhosis
None of the trials reported cirrhosis.
Proportion of participants with hepatocellular
carcinoma
None of the trials reported hepatocellular carcinoma.
Proportion of participants with chronic HCV infection
Nine trials (467 participants) reported chronic HCV infection as
measured by absence of sustained virological response (i.e. the pres-
ence of circulating virus at least six months after cessation of treat-
ment) (Omata 1991; Genesca 1993; Hwang 1994; Lampertico
1994; Omata 1994; Calleri 1998; Csatary 1998; Deterding 2013;
Santantonio 2014) (Analysis 1.5). The proportion of people with
chronic HCV infection was lower in the interferon-alpha and in-
terferon-beta groups than in the no intervention group using the
fixed-effect model (interferon-alpha: OR 0.27, 95% CI 0.09 to
0.76; participants = 99; trials = 3; I2 = 0%; interferon-beta: OR
0.07, 95% CI 0.00 to 1.24; participants = 90; trials = 3; I2 =
81%). Using the random-effects model, there was no change in
the results from the interferon-alpha versus the no intervention
group (OR 0.27, 95% CI 0.09 to 0.76). However, there was no
evidence of a difference between the interferon-beta versus the no
intervention groups on using the random-effects model (OR 0.07,
95% CI 0.00 to 1.24). There was no evidence of difference in
the proportion of participants with chronic HCV in the compar-
ison between the MTH-68/B vaccine versus the no intervention
groups (OR 0.28, 95% CI 0.05 to 1.65; participants = 41; trials =
1) and that between the pegylated interferon-alpha plus ribavirin
versus the pegylated interferon-alpha groups (OR 0.86, 95% CI
0.41 to 1.79; participants = 237; trials = 2; I2 = 0%).
Subgroup analysis
We did not perform any of the subgroup analyses as none of the
trials were at low risk of bias, the trials did not report the data for
different genotypes separately, and because there were few trials
for performing a meaningful subgroup analysis based on dosage.
Reporting bias
We did not explore reporting bias using funnel plots because of
the few trials included in the review.
Trial Sequential Analysis
Four comparisons had more than one trial and were eligible for
Trial Sequential Analysis. The Z-curves did not cross the trial se-
quential monitoring boundaries for any of the comparisons ex-
cept for chronic HCV in pegylated interferon-alpha plus ribavirin
versus pegylated interferon-alpha, where it has reached the futility
zone (Figure 4; Figure 5; Figure 6; Figure 7); when a relative risk
reduction of 10% was used, the Z-curve did not cross any of the
trial sequential monitoring boundaries for chronic HCV in pegy-
lated interferon-alpha plus ribavirin versus pegylated interferon-
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alpha as well (Figure 7). The Trial Sequential Analysis-adjusted
CIs were as follows.
Figure 4. Trial Sequential Analysis of serious adverse events (proportion) for pegylated interferon-alpha
plus ribavirin versus pegylated interferon-alpha performed using an alpha error of 2.5%, power of 90% (beta
error of 10%), relative risk reduction (RRR) of 20%, control group proportion observed in trials (Pc = 7%), and
observed heterogeneity in the trials (0%) shows that the accrued sample size was only a small fraction of the
diversity-adjusted required information size (DARIS); so the trial sequential monitoring boundaries were not
drawn. The Z-curve (blue line) does not cross the conventional boundaries (dotted green line). There was a
high risk of random errors.
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Figure 5. Trial Sequential Analysis of chronic hepatitis C virus for interferon-alpha versus no intervention
was performed using an alpha error of 1.6%, power of 90% (beta error of 10%), relative risk reduction (RRR) of
20%, control group proportion observed in trials (Pc = 84%; upper figure) and Pc = 20% (lower figure), and
observed diversity in the trials (0%). The upper figure with Pc = 84% shows that the accrued sample size was
only a small fraction of the diversity-adjusted required information size (DARIS). The Z-curve (blue line)
crosses the conventional boundaries (dotted green line), but it does not cross any of the trial sequential
monitoring boundaries (dotted red lines). The lower figure with Pc = 20% shows that the accrued sample size
was so small that trial sequential monitoring boundaries were not drawn. There is a high risk of random errors.
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Figure 6. Trial Sequential Analysis of chronic hepatitis C virus for interferon-beta versus no intervention
performed using an alpha error of 1.6%, power of 90% (beta error of 10%), relative risk reduction (RRR) of 20%,
control group proportion observed in the trials (Pc = 84%; upper figure) and a Pc of 20% (lower figure), and
observed heterogeneity in the trials (84%) shows that the accrued sample size was only a small fraction of the
diversity-adjusted required information size (DARIS); so the trial sequential monitoring boundaries were not
drawn. The Z-curve (blue line) crosses the conventional boundaries (dotted green line). There is a high risk of
random errors.
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Figure 7. Trial Sequential Analysis of chronic hepatitis C virus infection for pegylated interferon-alpha plus
ribavirin versus pegylated interferon-alpha performed using an alpha error of 1.6%, power of 90% (beta error of
10%), relative risk reduction (RRR) of 20% (top figure and bottom figure) and 10% (middle figure), control
group proportion observed in the trials (Pc = 84%; top figure and middle figure) and Pc = 20% (bottom figure),
and observed heterogeneity in the trials (0%) shows that the Z-curve (blue line) has reached the zone of futility
for a RRR of 20% (top figure). However, when a RRR of 10% or when a Pc = 20% was used, the accrued sample
size was only a small fraction of the diversity adjusted required information size (DARIS); the Z-curve (blue
line) does not cross the conventional boundaries (dotted green line) or trial sequential monitoring boundaries
(dotted red line) (middle figure). For a Pc = 20%, the accrued sample size was so small that the trial sequential
monitoring boundaries were not drawn. There is a high risk of random errors.
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• Serious adverse events: pegylated interferon-alpha plus
ribavirin versus pegylated interferon-alpha: could not be
calculated because of too little information.
• Chronic HCV: alpha interferon versus no intervention:
0.23 (95% CI 0.02 to 2.19).
• Chronic HCV: alpha interferon versus no intervention:
could not be calculated because of too little information.
• Chronic HCV: pegylated interferon-alpha plus ribavirin
versus pegylated interferon-alpha: 0.85 (95% CI 0.31 to 2.34)
and relative risk reduction of 10%: 0.85% (95% CI 0.04 to
17.00).
In addition, as a post hoc sensitivity analysis, we used a control
group proportion of 20% because the control group proportion
observed in the trials was higher than the expected proportion of
progression of acute HCV to chronic HCV. This revealed that
the accrued sample was so small that none of the trial sequential
monitoring boundaries were drawn.
Quality of evidence
None of the trials was at low risk of bias in all the domains. As
a result, the quality of evidence was downgraded two levels for
risk of bias in the trials in all the comparisons. In addition, the
quality of evidence was downgraded one level for imprecision be-
cause of the small sample size for all the comparisons. The quality
of evidence was downgraded by one more level for imprecision
because of wide CIs for all comparisons and one more level for
inconsistency because of substantial heterogeneity in magnitude
of effect for some comparisons. Overall, the quality of evidence
was very low for all comparisons (Summary of findings for the
main comparison; Summary of findings 2).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Intervention versus no intervention or control intervention (control) for acute hepatitis C infection: secondary outcomes
Patient or population: people with acute hepat it is C infect ion
Intervention: mult iple (see below)
Control: mult iple (see below)
Settings: secondary or tert iary care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Intervention
Liver transplantation None of the trials reported this outcome.
Decompensated liver dis-
ease
None of the trials reported this outcome.
Cirrhosis None of the trials reported this outcome.
Hepatocellular carcinoma None of the trials reported this outcome.
Chronic HCV infection†- in-
terferon-alpha versus no
intervention
848 per 1000 601 per 1000
(334 to 809)
OR 0.27
(0.09 to 0.76)
99
(3 RCTs)
⊕©©©
Very low1,2
Chronic HCV infection†- in-
terferon-beta versus no in-
tervention
833 per 1000 259 per 1000
(0 to 861)
OR 0.07
(0 to 1.24)
90
(3 RCTs)
⊕©©©
Very low1,2,3,4
Chronic HCV infection†-
M TH-68/ B vaccine versus
no intervention
263 per 1000 91 per 1000
(18 to 371)
OR 0.28
(0.05 to 1.65)
41
(1 RCT)
⊕©©©
Very low1,2,3
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Chronic HCV infection†-
pegylated interferon-alpha
plus ribavirin versus pegy-
lated interferon-alpha
204 per 1000 181 per 1000
(95 to 315)
OR 0.86
(0.41 to 1.79)
237
(2 RCTs)
⊕©©©
Very low1,2,3
* The basis for the assumed risk is the mean control group proport ion. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervent ion (and its 95% CI).
†Chronic HCV infect ion was measured by absence of sustained virological response (i.e. the presence of circulat ing virus at least 6 months af ter cessat ion of treatment)
CI: conf idence interval; HCV: hepat it is C virus; OR: odds rat io; RCT: randomised clinical trial.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded 2 levels for high risk of bias (i.e. within study risk of bias).
2 Downgraded 1 level for small sample size (i.e. imprecision).
3 Downgraded 1 level for wide conf idence intervals (i.e. imprecision).
4 Downgraded 1 level (substant ial heterogeneity in magnitude of ef fect) (i.e. heterogeneity).
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D I S C U S S I O N
Summary of main results
A total of 488 participants in 10 trials were included in this review.
A total of 467 participants in nine trials contributed to one or
more outcomes. A total of six interventions were evaluated in the
nine trials that contributed with analysis data to the review. The
interventions included interferon-alpha, interferon-beta, MTH-
68/B vaccine, pegylated interferon-alpha, pegylated interferon-al-
pha plus ribavirin, all versus no intervention in the control groups
(except pegylated interferon-alpha plus ribavirin, which was com-
pared with pegylated interferon-alpha). None of the trials com-
pared direct-acting antivirals versus placebo or other interventions.
Overall, the mortality at six months to one year following treat-
ment in people with acute HCV infection was very low. Only one
of the participants died during this period. There was no evidence
of differences in proportion of people with serious adverse events
or number of serious adverse events in any of the comparisons.
However, it should be noted that 7.0% of the people receiving
pegylated interferon-alpha and 11.5% of the people receiving pe-
gylated interferon-alpha plus ribavirin developed serious adverse
events. The proportion of people with adverse events was higher in
the interferon-alpha and interferon-beta groups with 87.5% (14/
16) and 40% (8/20) of people developing one or more adverse
events.
The proportion of people with acuteHCVwho developed chronic
HCV asmeasured by lack of sustained virological response was ap-
proximately 84% in the no intervention group. This appears very
high in relation to the conventional wisdom that only about 20%
of people develop chronic HCV. This may be due to the definition
used for chronicHCV, that is, presence of circulating virus after six
months, rather than the presence of active hepatitis, which involves
some measure of inflammation such as abnormal transaminases or
biopsy which demonstrates inflammation. Only a proportion of
people with circulatingHCV virus develop chronic inflammation.
This may be the reason for the difference in the chronic HCV
proportions observed in this review and the conventional wisdom.
The proportion of people who developed chronic HCV infection
as measured by lack of sustained virological response was less in
the interferon-alpha versus the no intervention groups. However,
the Trial Sequential Analysis showed that the Z-curve did not cross
the trial sequential monitoring boundaries indicating that further
trials are required to confirm this finding. Long-term follow-up
and assessment of clinical outcomes such as cirrhosis, decompen-
sated cirrhosis, and requirement for liver transplantation are nec-
essary to confirm that this translates into clinical benefit. However,
none of the trials reported these outcomes. So, we are unable to
conclude that interferon-alpha is clinically beneficial.
None of the trials reported health-related quality of life, and so,
we were unable to determine the impact of these drugs on health-
related quality of life.
Overall completeness and applicability of
evidence
We have included all the major treatments used for treating acute
HCV infection in this review. We found no trials comparing pe-
gylated interferon or direct acting antivirals versus placebo or any
other intervention. While we found trials comparing different sec-
ond-generation antivirals with each other, we did not find any tri-
als comparing second-generation antivirals with first-generation
antivirals or any form of interferons, that is, none of the trials com-
paring different second-generation antivirals were eligible for this
review. One possible reason is the difficulty in distinguishing be-
tween acute HCV infection and chronic HCV infection. As most
people are asymptomatic after acute HCV infection (Hajarizadeh
2012), the only definitive way of diagnosis of acuteHCV infection
is to have a baseline sample with absent HCV antibody and HCV
RNA followed by presence of HCV antibody or HCV RNA, but
it is uncommon in clinical practice (Hajarizadeh 2012). So, the
clinicians might consider that the person has chronic HCV infec-
tion and treat them accordingly. Another possible reason is that
clinicians may feel that the effectiveness of a treatment may not
be dependent on whether someone has infection for less than six
months (acute HCV infection) or more than six months (chronic
HCV infection). So, the clinicians may use the same treatment
as for chronic HCV infection. Both these reasons (difficulty in
establishing a diagnosis of acute HCV infection and the belief that
the treatment effect in people with less than six months of dura-
tion of HCV infection is probably the same as that in more than
six months of HCV infection) contribute to the very few trials
conducted in this field. So, it is not clear whether the findings of
this review are applicable in the current clinical setting. If they
are applicable, they are applicable only in people who have not
undergone liver transplantation and those who do not have other
coexisting viral diseases as we excluded such trials.
Quality of the evidence
The overall quality of evidence was very low for all the outcomes.
All the trials were at high risk of bias for at least one of the domains,
mainly because blinding of participants and healthcare providers
was not performed in any of the trials and due to risk of industry
bias (Lundh 2017). There were risks of bias in other domains also
as shown in Figure 1 and Figure 2. The sample size was small for
all the comparisons. There were also wide CIs (the CIs overlapped
20% increase or decrease and no effect) for many of the compar-
isons. In general, there was no evidence of heterogeneity in most
comparisons with the exception of the chronic HCV infection in
the comparison interferon-beta versus no intervention.
Potential biases in the review process
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We followed the guidance of theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) with two review authors
independently selecting trials and extracting data.We performed a
thorough search of literature. However, the search period included
the premandatory trial registration era and it is possible that some
trials on treatments that were not effective or were harmful were
not reported at all.
We only included randomised clinical trials which are known to
focus mostly on benefits and do not collect and report harms in
a detailed manner. According to our choice of studies (i.e. only
randomised clinical trials), wemight havemissed a large number of
studies that addressed reporting of harms. Accordingly, this review
is biased towards benefits ignoring harms.
We did not search for interventions and trials registered at regu-
latory authorities (e.g. US Food and Drug Administration, Euro-
peanMedicines Agency, etc.). This may have overlooked trials and
as such trials usually are unpublished, the lack of inclusion of such
trials may make our comparisons look more advantageous than
they really are. However, this is of academic interest only because
there is no evidence of benefit of any treatment in people with
acute HCV infection, that is, there is no reason to suggest that
any of the treatments should be used in routine clinical practice
regardless of the adverse event profile of the treatment.
We planned to perform a network meta-analysis. However, it was
not possible to assess whether the potential effect modifiers were
similar across different comparisons. Performing a network meta-
analysis in this scenario can be misleading. Therefore, we did not
perform the network meta-analysis, and assessed the compara-
tive benefits and harms of different interventions using standard
Cochrane methodology.
Agreements and disagreements with other
studies or reviews
We agree with the Cochrane systematic review on interferon ther-
apy of acute HCV that interferons may improve the sustained vi-
rological response, but the clinical effects of the interferons are not
known (Myers 2001).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Very low quality evidence suggests that interferon-alpha may de-
crease the incidence of chronic hepatitis C virus (HCV) infection
as measured by lack of sustained virological response. However,
the clinical impact (such as improvement in health-related quality
of life, reduction in cirrhosis, decompensated liver disease, and
liver transplantation) has not been reported. It is also not clear
whether this finding is applicable in the current clinical setting
dominated by the use of pegylated interferons and direct-acting
antivirals, although we did not find any evidence to support that
pegylated interferons or ribavirin or both, are effective in people
with acute HCV infection. We could find no randomised clinical
trials comparing direct-acting antivirals versus placebo or other
interventions for acute HCV infection. There is significant uncer-
tainty in the benefits and harms of the interventions, and high-
quality randomised clinical trials are required.
Implications for research
The trial design that is most likely to be accepted by hepatolo-
gists will probably involve direct-acting antivirals and pegylated
interferon. Researchers should use clinical outcomes for research
on this topic. The ideal trial should include placebo as one of the
intervention arms because there has been no evidence from ran-
domised clinical trials that any of the interventions are effective in
improving clinical outcomes. However, as many hepatologists and
researchers believe that sustained virological response equates to
cure of disease (although, this belief has been challenged (Gluud
2014; Koretz 2015)), it may be difficult to recruit into such a trial.
The trials should be designed and reported using guidance from
the SPIRIT statement (Standard Protocol Items: Recommenda-
tions for Interventional Trials; Chan 2013) and the CONSORT
statement (Schulz 2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Calleri 1998
Methods Randomised clinical trial.
Participants Country: Italy.
Number randomised: 40.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 40.
Mean age: 29 years.
Females: 6 (15%).
Genotype 1: not stated.
Genotype 3: not stated.
Other genotypes: not stated.
Mean follow-up period in months (for all groups): 22.5.
Inclusion criteria
• Elevated serum alanine aminotransferase levels (above 300 IU/L).
• Seroconversion from negative to positive anti-HCV.
Exclusion criteria
• Other causes of acute liver damage.
• Heavy alcohol intake (> 40 g/day).
• Fulminant hepatitis.
• History of chronic liver disease or severe non-liver diseases (cancer, chronic renal
failure, chronic heart failure).
• HBV and HIV carriers.
• Pregnant women.
Interventions Participants were randomly assigned to 2 groups.
Group 1: interferon-beta (n = 20).
Further details: interferon-beta 3 MU IM once daily for 5 days then 3 times per day for
3 more weeks
Group 2: no intervention (n = 20).
Duration of treatment: 1 month.
Outcomes Sustained virological response.
Biochemical response.
Severity and frequency of adverse events.
Notes 6 participants were not randomised for logistical issues and they were allocated to the
immediate treatment
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomized, computer generated according to the
author’s reply.”
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Calleri 1998 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: “different treatments” (author replies).
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: “different treatments” (author replies).
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Low risk Quote: “Italian NHS”.
Comment: according to the author’s reply.
Other bias Low risk Comment: no other risk of bias.
Csatary 1998
Methods Randomised clinical trial.
Participants Country: Hungary, USA.
Number randomised: 41.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 41.
Mean age: not stated.
Females: not stated.
Genotype 1: not stated.
Genotype 3: not stated.
Other genotypes: not stated.
Mean follow-up period in months (for all groups): 12.
Inclusion criteria
• Anti-HCV positive.
• Hospitalisation because of jaundice, other clinical signs of acute hepatitis (fever,
severe malaise, loss of appetite) and a 10- to 100-fold elevation of alanine
aminotransferase level.
Exclusion criteria
• Positivity for HAV, HBV, Epstein-Barr virus, cytomegalovirus.
• HIV positivity.
• Suspicion or evidence of alcohol-induced or drug-induced hepatitis.
• Clinical or histological signs of chronic hepatitis as well as other chronic liver
diseases.
• Fulminant hepatitis.
• Malignancies.
• Underlying systemic disease.
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Csatary 1998 (Continued)
• Immunosuppressive treatment within 6 months.
• Pregnancy.
• Lack of compliance.
Interventions Participants were randomly assigned to 2 groups.
Group 1: MTH-68/B (n = 22).
Further details:MTH-68/B (live attenuated infectious bursal disease virus (IBDV)) 4000
U/day for 1 week, then 3 times per week for 2 weeks, then once monthly for 6 months
Group 2: no intervention (n = 19).
Duration of treatment: 6 months
Outcomes Sustained virological response.
Frequency of adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly allocated to two groups.”
Comment: further details not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no use of placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other bias.
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Deterding 2013
Methods Randomised clinical trial.
Participants Country: Germany.
Number randomised: 107.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 107.
Mean age: 39 years.
Females: 46 (43%).
Genotype 1: 73 (68.2%).
Genotype 3: 18 (16.8%).
Other genotypes: 10 (9.3%).
Mean follow-up period in months (for all groups): 6.
Inclusion criteria
• Aged > 18 years.
• Acute HCV infection: seroconversion for antibodies against HCV documented
OR proven/very likely exposure to HCV within the preceding 4 months combined
with a serum ALT level of at least 10-times the upper limit of normal range with no
evidence of any pre-existing disorder.
• ≥ 1 of right upper abdominal pain, jaundice, influenza-like symptoms, fatigue.
Exclusion criteria
• People who had other causes of liver disease as assessed by standard clinical and
laboratory criteria.
• HBV infection.
• HIV coinfection.
• People with ongoing uncontrolled misuse of alcohol or IV drugs.
• Autoimmune diseases.
• Absolute neutrophil count < 1500 cells/mm3.
• Thrombocytopenia (< 70000 cells/mm3).
• Anaemia (< 11 g/dL in women and < 12 g/dL in men).
• Decompensated liver disease.
• Decompensated renal disease.
• Decompensated thyroid disease.
• Psychiatric conditions.
• History of seizures.
• Poorly controlled diabetes mellitus.
• Ophthalmological disease.
• Immunologically mediated disease.
• History of chronic pulmonary disease or cardiac disease.
• Pregnancy.
• History of transplantation or malignancy.
Interventions Participants were randomly assigned to 2 groups.
Group 1: immediate pegylated interferon-alpha-2b (n = 55).
Further details: immediate pegylated interferon-alfa-2b 1.5 µg/kg
Group 2: delayed pegylated interferon-alfa-2b (n = 52).
Further details: delayed pegylated interferon-alfa-2b 1.5 µg/kg + ribavirin > 10.6 mg/kg
Duration of treatment: 6 months.
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Deterding 2013 (Continued)
Outcomes Sustained virological response.
Biochemical response.
Severity and frequency of adverse events.
Analysis of responses to the respective treatment approaches according to severity of
symptoms
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised via a web-based ran-
domisation service provided by the Hep-Net Study House.
”
Allocation concealment (selection bias) Unclear risk Quote: “We used stratified block randomisation with block
sizes of eight, independent across strata.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “This investigator-initiated study was designed as
an open-label, phase 3, multicentre study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: outcome assessors blind according to the author
reply
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “The study was supported by the German Network
of Competence on Viral Hepatitis (Hep-Net, funded by the
Federal Ministry of Education and Research). The study
was also supported by a research grant from Essex Pharma,
Schering-Plough, and MSD. MSD provided study drugs
and financial support.”
Other bias Low risk Comment: no other bias.
Genesca 1993
Methods Randomised clinical trial.
Participants Country: Spain.
Number randomised: 28.
Post-randomisation dropouts: 0 (0%).
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Genesca 1993 (Continued)
Revised sample size: 28.
Mean age: not stated.
Females: not stated.
Genotype 1: not stated.
Genotype 3: not stated.
Other genotypes: not stated.
Mean follow-up period in months (for all groups): 12 months.
Inclusion criteria
• Acute HCV.
Interventions Participants were randomly assigned to 2 groups.
Group 1: interferon-alpha-2b (n = 15).
Further details: interferon-alpha-2b 3 MU 3 times per week.
Group 2: no treatment (n = 13).
Duration of treatment: 3 months.
Outcomes Sustained virological response.
Biochemical response.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “A randomised, controlled trial was undertaken.”
Comment: further details not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Twenty eight patients with acute HCV (15 treated
and 13 controls) were included in the trial.”
Comment: placebo not used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: some important outcomes which would gener-
ally be assessed were not reported
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: no other bias.
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Hwang 1994
Methods Randomised clinical trial.
Participants Country: China.
Number randomised: 33.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 33.
Mean age: 54 years.
Females: 9 (27.3%).
Genotype 1: not stated.
Genotype 3: not stated.
Other genotypes: not stated.
Mean follow-up period in months (for all groups): 12.
Inclusion criteria
• People who received blood transfusion due to cardiovascular surgery, other
operations, or upper gastrointestinal bleeding in Veterans General Hospital, Taipei.
• Diagnosis of acute HCV infection: serum ALT elevated above 90 IU/L (twice the
upper normal value) and the seroconversion of serum antibody to HCV (anti-HCV) or
serum HCV-RNA after blood transfusion.
Exclusion criteria
• Estimated survival < 6 months.
• History of interferon treatment within 12 months prior to entering trial.
• Presence of severe systemic diseases or malignancies.
• Women of childbearing age not using contraception and breastfeeding mothers.
• Age < 18 years.
• Evidence of haematopoietic dysfunction.
• Presence of decompensated liver conditions such as hepatic encephalopathy,
ascites, or a serum bilirubin level > 4 mg/dL.
• Presence of any concurrent illness that could interfere with the investigator’s
assessment in the treatment of hepatitis.
• Psychiatric disorders.
Interventions Participants were randomly assigned to 2 groups.
Group 1: interferon-alpha-2b (n = 16).
Further details: interferon-alpha-2b 3 MU 3 times per week.
Group 2: no treatment (n = 17).
Duration of treatment: 3 months.
Outcomes Sustained virological response.
Frequency of adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “These patients were randomly allocated to either
the IFN-treated group or the control group by a random
number table.”
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Hwang 1994 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Seventeen patients in the control group received
no specific treatment.”
Comment: placebo not used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Only one patient in the control group was unwill-
ing to continue andwithdrew from the study after 6months
of follow up.”
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: all important outcomes were reported.
For-profit bias High risk Quote: “This study was supported by grants from the Na-
tional Science Council (NSC82-0419-B075-092) and Na-
tional Health Research Institutes (DOH-83-HR-208), Re-
public of China. Drug supplied by pharm. company.”
Other bias Low risk Comment: no other bias.
Lampertico 1994
Methods Randomised clinical trial.
Participants Country: Italy.
Number randomised: 41.
Post-randomisation dropouts: 3 (7.3%).
Revised sample size: 38.
Mean age: 47 years.
Females: 19 (50%).
Genotype 1: not stated.
Genotype 3: not stated.
Other genotypes: not stated.
Mean follow-up period in months (for all groups): 18.
Inclusion criteria
• Post-transfusion acute non-A, non-B/type C hepatitis: increase of serum ALT
level to > 2.5 times the upper normal limit, on 2 separate occasions at least 2 weeks
apart between 2 weeks and 6 months after transfusion.
Exclusion criteria
• Aged > 60 years.
• Pregnancy.
• Previous transfusion with blood, fresh frozen plasma, or clotting factor
concentrates.
• Treatment with immunosuppressive drugs.
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Lampertico 1994 (Continued)
• Malignant tumours.
• Antibody to HIV.
Interventions Participants were randomly assigned to 2 groups.
Group 1: interferon-alpha-2b (n = 22).
Further details: interferon-alpha-2b 3 MU IM 3 times per week
Group 2: no treatment (n = 16).
Duration of treatment: 3 months.
Outcomes Sustained virological response.
Biochemical response.
Mortality at the end of follow-up (18 months).
Notes Reasons for post-randomisation dropouts: of the 48 participants enrolled in the study,
1 refused therapy and 2 untreated people were lost to follow-up during month 1. 7
participants (16% of total) were thought to have been infected with a non-A, non-B,
non-C agent
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: randomisation was computerised according to
the author’s reply
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: multicentre, prospective, open, randomised
study comparing interferon treatment and no treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: some important outcomes which would gener-
ally be assessed were not reported
For-profit bias High risk Quote: “We thank Dr. Paola Mazzanti and Dr. Cristina
Pintus (Schering-Plough) for their assistance.”
Other bias Low risk Comment: there was no other bias.
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Omata 1991
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 27.
Post-randomisation dropouts: 2 (7.4%).
Revised sample size: 25.
Mean age: 40 years.
Females: 14 (56%).
Genotype 1: not stated.
Genotype 3: not stated.
Other genotypes: not stated.
Mean follow-up period in months (for all groups): 36.
Inclusion criteria
• Serum ALT > 200 IU after transfusion or raised serum ALT without a history of
taking hepatotoxic drug or of heavy alcohol intake.
• Seronegativity for hepatitis B surface antigen, IgM antibody to HBV core protein,
IgM-HA antibody, HBV-DNA, and autoimmune markers.
• Liver histology compatible with the diagnosis of acute hepatitis.
Interventions Participants were randomly assigned to 2 groups.
Group 1: interferon-beta (n = 11).
Further details: interferon-beta, 3 MU IV for 5 consecutive days in the first week, and
then 3 times per week for the next 3 weeks
Group 2: no treatment (n = 14).
Duration of treatment: 1 month.
Outcomes Sustained virological response.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “25patientswith acute non-A, non-Bhepatitis drew
lots for allocation to treatment with interferon.”
Allocation concealment (selection bias) Low risk Quote: “25patientswith acute non-A, non-Bhepatitis drew
lots for allocation to treatment with interferon.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: placebo not used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
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Omata 1991 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “2 patients in the untreated group were lost to fol-
low-up.”
Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: some important outcomes which would gener-
ally be assessed were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: there was no other bias.
Omata 1994
Methods Randomised clinical trial.
Participants Country: Japan.
Number randomised: 25.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 25.
Mean age: 39 years.
Females: 14 (56%).
Genotype 1: not stated.
Genotype 3: not stated.
Other genotypes: not stated.
Mean follow-up period in months (for all groups): 36.
Inclusion criteria
• Serum ALT > 200 IU after transfusion, or elevated serum ALT without a history
of transfusion, hepatotoxic drugs, or heavy alcohol intake.
• Liver histology compatible with the diagnosis of acute hepatitis.
Exclusion criteria
• Seronegativity for hepatitis B surface antigen, IgM antibody to HBV core protein,
IgM anti-HA, HBV-DNA, and autoimmune markers.
Interventions Participants were randomly assigned to 2 groups.
Group 1: interferon-beta (n = 11).
Further details: interferon-beta 3 MU IV for 5 days, then 3 times per week for 3 weeks
Group 2: no treatment (n = 14).
Duration of treatment: 1 month.
Outcomes Sustained virological response.
Fluctuation of ALT concentrations.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Omata 1994 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “25 patients randomly assigned to.”
Comment: further details not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no use of placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: some important outcomes which would gener-
ally be assessed were not reported
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: there was no other bias.
Santantonio 2014
Methods Randomised clinical trial.
Participants Country: Italy.
Number randomised: 130.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 130.
Mean age: 34 years.
Females: 41 (31.5%).
Genotype 1: 53 (40.8%).
Genotype 3: 32 (24.6%).
Other genotypes: 45 (34.6%).
Mean follow-up period in months (for all groups): 12.
Inclusion criteria
• Aged 18 to 65 years.
• Diagnosis of acute HCV infection: documented anti-HCV seroconversion or,
alternatively, abrupt increase of transaminases > 20 times the upper limit of the normal
range.
• Absence of other hepatitis viruses (HAV, HBV) or toxic hepatitis in previously
healthy people.
• HCV-RNA positive.
• Acute hepatitis C still viraemic after 12 weeks of observation from disease onset.
Exclusion criteria
• Liver disease unrelated to HCV infection.
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Santantonio 2014 (Continued)
• Haemoglobin < 12 g/dL in women and 13 g/dL in men.
• White blood count < 3000/µL.
• Platelets < 100,000/µL.
• Pregnancy.
• History of severe psychiatric disease.
• Neurological disease.
• Severe cardiac, gastrointestinal, and kidney disease.
• Infection with HBV or HIV.
• Positive antinuclear antibodies or antismooth muscle antibody (titre > 1/80), or
both.
• History of having received any systemic antineoplastic or immunomodulatory
treatment in the previous 6 months.
• History or other evidence of severe illness or any other conditions that would
make people unsuitable for the study (alcohol intake at a daily dose > 40 g for males
and > 30 g for females, thalassaemia, and dialysis).
• People with ongoing drug abuse.
Interventions Participants were randomly assigned to 3 groups.
Group 1: pegylated interferon-alpha-2b (n = 44).
Further details: pegylated interferon-alpha-2b 1.5 µg/kg/week (24 weeks)
Group 2: pegylated interferon-alpha-2b (n = 43).
Further details: pegylated interferon-alpha-2b 1.5 µg/kg/week (12 weeks)
Group 3: pegylated interferon-alpha-2b plus ribavirin (n = 43)
Further details: pegylated interferon-alpha-2b 1.5 µg/kg/week + ribavirin 10.6 mg/kg/
day orally (12 weeks)
Duration of treatment: 12 to 24 weeks (see above).
Outcomes Sustained virological response.
Virological responses after 2 weeks of treatment (very rapid virological response), after 4
weeks of treatment (rapid virological response), at the end of treatment (end-of-treatment
virological response), and at 12 months’ post-treatment follow-up (long-term virological
response)
ALT level normalisation at the end of treatment and at 6 and 12 months’ post-treatment
follow-up
Safety (adverse events).
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization list was generated centrally by
an independent biostatistician using the Proc Plan of the
SAS system (version 9.2; SAS Institute Inc., Cary, NC) and
consisted of a computer-generated treatment allocation list
in blocks of 9 patients each.”
Allocation concealment (selection bias) Unclear risk Comment: information not available.
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Santantonio 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: different treatments, no placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “ITT analysis, Patients who discontinued the study
for any reason before the 6-month follow-up visit were con-
sidered as nonresponders.”
Comment: low for sustained virological response, high for
1-year mortality because there were post-randomisation
dropouts
Selective reporting (reporting bias) High risk Comment: adverse events not clearly reported.
For-profit bias High risk Quote: “The study sponsor for drug supply and financial
support was Schering-Plough (now Merck) SpA, Milan,
Italy.”
Other bias Low risk Comment: there was no other bias.
Wang 2005
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 21.
Post-randomisation dropouts: 0 (0%).
Revised sample size: 21.
Mean age: not stated.
Females: not stated.
Genotype 1: 13 (61.9%).
Genotype 3: not stated.
Other genotypes: not stated.
Mean follow-up period in months (for all groups): 6.
Inclusion criteria
• Seroconversion to anti-HCV positive within 6 months of screening in a
previously seronegative IV drug users.
• Detectable serum HCV.
• No contraindications to pegylated interferon.
Interventions Participants were randomly assigned to 2 groups.
Group 1: pegylated interferon-alpha (n = 9).
Further details: pegylated interferon-alpha (no further details of treatment regimen)
Group 2: no treatment (n = 12).
Duration of treatment: 6 months.
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Wang 2005 (Continued)
Outcomes Sustained virological response was reported but was not reported in sufficient details to
include for analysis
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: information not available.
Allocation concealment (selection bias) Unclear risk Comment: information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: information not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: information not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation dropouts.
Selective reporting (reporting bias) High risk Comment: some important outcomes which would gener-
ally be assessed were not reported
For-profit bias Unclear risk Comment: information not available.
Other bias Low risk Comment: there was no other bias.
ALT: alanine transaminase; DNA: deoxy ribonucleic acid; HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus;
HCV-RNA: hepatitis C virus ribonucleic acid; IM: intramuscular; ITT: intention-to-treat analysis; IU: international units; IV:
intravenous; MU: million units.
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D A T A A N D A N A L Y S E S
Comparison 1. Intervention versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events
(proportion)
4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Interferon-beta versus no
intervention
1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 MTH-68/B vaccine versus
no intervention
1 41 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Pegylated interferon-alpha
plus ribavirin versus pegylated
interferon-alpha
2 237 Odds Ratio (M-H, Fixed, 95% CI) 1.72 [0.70, 4.21]
2 Serious adverse events (number) 4 Rate Ratio (Fixed, 95% CI) Subtotals only
2.1 Interferon-beta versus no
intervention
1 40 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 MTH-68/B vaccine versus
no intervention
1 41 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Pegylated interferon-alpha
plus ribavirin versus pegylated
interferon-alpha
2 237 Rate Ratio (Fixed, 95% CI) 2.74 [1.40, 5.33]
3 Adverse events (proportion) 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Interferon-alpha versus no
intervention
1 33 Odds Ratio (M-H, Fixed, 95% CI) 203.0 [9.01, 4574.
81]
3.2 Interferon-beta versus no
intervention
1 40 Odds Ratio (M-H, Fixed, 95% CI) 27.88 [1.48, 526.12]
3.3 MTH-68/B vaccine versus
no intervention
1 41 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events (number) 2 Odds Ratio (Fixed, 95% CI) Subtotals only
4.1 Interferon-beta versus no
intervention
1 40 Odds Ratio (Fixed, 95% CI) 17.00 [0.98, 294.53]
4.2 MTH-68/B vaccine versus
no intervention
1 41 Odds Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Chronic HCV infection 9 Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Interferon-alpha versus no
intervention
3 99 Odds Ratio (M-H, Random, 95% CI) 0.27 [0.09, 0.76]
5.2 Interferon-beta versus no
intervention
3 90 Odds Ratio (M-H, Random, 95% CI) 0.07 [0.00, 1.24]
5.3 MTH-68/B vaccine versus
no intervention
1 41 Odds Ratio (M-H, Random, 95% CI) 0.28 [0.05, 1.65]
5.4 Pegylated interferon-alpha
plus ribavirin versus pegylated
interferon-alpha
2 237 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.41, 1.79]
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Analysis 1.1. Comparison 1 Intervention versus control, Outcome 1 Serious adverse events (proportion).
Review: Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis
Comparison: 1 Intervention versus control
Outcome: 1 Serious adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Interferon-beta versus no intervention
Calleri 1998 0/20 0/20 Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 MTH-68/B vaccine versus no intervention
Csatary 1998 0/22 0/19 Not estimable
Subtotal (95% CI) 22 19 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Pegylated interferon-alpha plus ribavirin versus pegylated interferon-alpha
Deterding 2013 11/52 7/55 73.9 % 1.84 [ 0.65, 5.18 ]
Santantonio 2014 2/43 3/87 26.1 % 1.37 [ 0.22, 8.50 ]
Subtotal (95% CI) 95 142 100.0 % 1.72 [ 0.70, 4.21 ]
Total events: 13 (Intervention), 10 (Control)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intervention Favours control
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Analysis 1.2. Comparison 1 Intervention versus control, Outcome 2 Serious adverse events (number).
Review: Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis
Comparison: 1 Intervention versus control
Outcome: 2 Serious adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Interferon-beta versus no intervention
Calleri 1998 20 20 0 (0) Not estimable
Subtotal (95% CI) 20 20 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 MTH-68/B vaccine versus no intervention
Csatary 1998 22 19 0 (0) Not estimable
Subtotal (95% CI) 22 19 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Pegylated interferon-alpha plus ribavirin versus pegylated interferon-alpha
Deterding 2013 52 55 1.1208 (0.366719) 86.1 % 3.07 [ 1.49, 6.29 ]
Santantonio 2014 43 87 0.299243 (0.912871) 13.9 % 1.35 [ 0.23, 8.07 ]
Subtotal (95% CI) 95 142 100.0 % 2.74 [ 1.40, 5.33 ]
Heterogeneity: Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.96 (P = 0.0031)
0.01 0.1 1 10 100
Favours intervention Favours control
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Analysis 1.3. Comparison 1 Intervention versus control, Outcome 3 Adverse events (proportion).
Review: Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis
Comparison: 1 Intervention versus control
Outcome: 3 Adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Interferon-alpha versus no intervention
Hwang 1994 14/16 0/17 100.0 % 203.00 [ 9.01, 4574.81 ]
Subtotal (95% CI) 16 17 100.0 % 203.00 [ 9.01, 4574.81 ]
Total events: 14 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.34 (P = 0.00083)
2 Interferon-beta versus no intervention
Calleri 1998 8/20 0/20 100.0 % 27.88 [ 1.48, 526.12 ]
Subtotal (95% CI) 20 20 100.0 % 27.88 [ 1.48, 526.12 ]
Total events: 8 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
3 MTH-68/B vaccine versus no intervention
Csatary 1998 0/22 0/19 Not estimable
Subtotal (95% CI) 22 19 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours control
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Analysis 1.4. Comparison 1 Intervention versus control, Outcome 4 Adverse events (number).
Review: Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis
Comparison: 1 Intervention versus control
Outcome: 4 Adverse events (number)
Study or subgroup Intervention Control log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Interferon-beta versus no intervention
Calleri 1998 20 20 2.833213 (1.455214) 100.0 % 17.00 [ 0.98, 294.53 ]
Subtotal (95% CI) 20 20 100.0 % 17.00 [ 0.98, 294.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
2 MTH-68/B vaccine versus no intervention
Csatary 1998 22 19 0 (0) Not estimable
Subtotal (95% CI) 22 19 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
0.002 0.1 1 10 500
Favours intervention Favours control
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Analysis 1.5. Comparison 1 Intervention versus control, Outcome 5 Chronic HCV infection.
Review: Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis
Comparison: 1 Intervention versus control
Outcome: 5 Chronic HCV infection
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon-alpha versus no intervention
Genesca 1993 7/15 9/13 44.8 % 0.39 [ 0.08, 1.84 ]
Hwang 1994 9/16 14/17 42.8 % 0.28 [ 0.06, 1.35 ]
Lampertico 1994 15/22 16/16 12.5 % 0.06 [ 0.00, 1.19 ]
Subtotal (95% CI) 53 46 100.0 % 0.27 [ 0.09, 0.76 ]
Total events: 31 (Intervention), 39 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
2 Interferon-beta versus no intervention
Calleri 1998 15/20 16/20 37.7 % 0.75 [ 0.17, 3.33 ]
Omata 1991 1/11 13/14 29.7 % 0.01 [ 0.00, 0.14 ]
Omata 1994 1/11 11/14 32.6 % 0.03 [ 0.00, 0.31 ]
Subtotal (95% CI) 42 48 100.0 % 0.07 [ 0.00, 1.24 ]
Total events: 17 (Intervention), 40 (Control)
Heterogeneity: Tau2 = 5.40; Chi2 = 10.47, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 1.82 (P = 0.069)
3 MTH-68/B vaccine versus no intervention
Csatary 1998 2/22 5/19 100.0 % 0.28 [ 0.05, 1.65 ]
Subtotal (95% CI) 22 19 100.0 % 0.28 [ 0.05, 1.65 ]
Total events: 2 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
4 Pegylated interferon-alpha plus ribavirin versus pegylated interferon-alpha
Deterding 2013 2/52 4/55 17.9 % 0.51 [ 0.09, 2.91 ]
Santantonio 2014 12/43 25/87 82.1 % 0.96 [ 0.43, 2.16 ]
Subtotal (95% CI) 95 142 100.0 % 0.86 [ 0.41, 1.79 ]
Total events: 14 (Intervention), 29 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours control
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A D D I T I O N A L T A B L E S
Table 1. Characteristics table
Study
name
Interven-
tion
Control Period of
follow-up
(months)
Randomi-
sation
Blinding
of partici-
pants and
health-
care pro-
fessionals
Blind-
ing of out-
come
assessors
Missing
outcome
bias
Selective
outcome
reporting
bias
For-profit
bias
Genesca
1993
Interferon-
alpha
No inter-
vention
12 Unclear High Unclear Low High Unclear
Hwang
1994
Interferon-
alpha
No inter-
vention
12 Unclear High Unclear High Low High
Lamper-
tico
1994
Interferon-
alpha
No inter-
vention
18 Unclear High Unclear High High High
Omata
1991
Interferon-
beta
No inter-
vention
36 Low High Unclear High High Unclear
Omata
1994
Interferon-
beta
No inter-
vention
36 Unclear High Unclear Low High Unclear
Calleri
1998
Interferon-
beta
No inter-
vention
22.5 Unclear High High Low Low Low
Csatary
1998
MTH-68/
B vaccine
No inter-
vention
12 Unclear High Unclear Low Low Unclear
Wang
2005
Pegylated
interferon-
alpha
No inter-
vention
6 Unclear Unclear Unclear High High Unclear
Deterding
2013
Pegylated
interferon-
alpha
Pegylated
interferon-
alpha plus
ribavirin
6 Unclear High Low High Low High
Santanto-
nio
2014
Pegylated
interferon-
alpha
Pegylated
interferon-
alpha plus
ribavirin
12 Unclear High Unclear Low High High
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A P P E N D I C E S
Appendix 1. Methods for network meta-analysis if we find this is possible in the future
Measures of treatment effect
Relative treatment effects
For dichotomous variables (e.g. proportion of participants with serious adverse events or any adverse events), we will calculate the odds
ratio with 95% credible interval (or Bayesian confidence interval) (Severini 1993). For continuous variables (e.g. quality of life reported
on the same scale), we will calculate the mean difference with 95% credible interval. We will use standardised mean difference values
with 95% credible interval for quality of life if included trials use different scales. For count outcomes (e.g. number of adverse events
and serious adverse events), we will calculate the rate ratio with 95% credible interval. For time-to-event data (e.g. mortality at maximal
follow-up), we will calculate hazard ratio with 95% credible interval.
Relative ranking
We will estimate the ranking probabilities for all treatments of being at each possible rank for each intervention. Then, we will obtain
the surface under the cumulative ranking curve (SUCRA) (cumulative probability) and rankogram (Salanti 2011; Chaimani 2013).
Unit of analysis issues
We will collect data for all trial treatment groups that meet the inclusion criteria. The codes for analysis, that we will use, accounts for
the correlation between the effect sizes from trials with more than two groups.
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity by carefully examining the characteristics and design of included trials. We
will assess the presence of clinical heterogeneity by comparing effect estimates under different categories of potential effect modifiers.
Different study designs and risk of bias may contribute to methodological heterogeneity.
We will assess statistical heterogeneity by comparing the results of the fixed-effect model meta-analysis and the random-effects model
meta-analysis, between-study standard deviation (tau2 and comparing this with values reported in the study of the distribution of
between-study heterogeneity (Turner 2012)), and by calculating the I2 statistic (using Stata/SE 14.2). If we identify substantial hetero-
geneity, clinical, methodological, or statistical, we will explore and address heterogeneity in a subgroup analysis (see ’Subgroup analysis
and investigation of heterogeneity for network meta-analysis’ section).
Assessment of transitivity across treatment comparisons
We will evaluate the plausibility of transitivity assumption (the assumption that the participants included in the different studies with
different immunosuppressive regimens can be considered to be a part of a multi-arm randomised clinical trial and could potentially
have been randomised to any of the treatments) (Salanti 2012). In other words, any participant that meets the inclusion criteria is, in
principle, equally likely to be randomised to any of the above eligible interventions. If there is any concern that the clinical safety and
effectiveness are dependent upon the effect modifiers, we will continue to do traditional Cochrane pair-wise comparisons and we will
not perform a network meta-analysis on all participant subgroups.
Assessment of reporting biases
For the network meta-analysis, we will judge the reporting bias by the completeness of the search (i.e. searching various databases and
including conference abstracts), as we do not currently find any meaningful order to perform a comparison-adjusted funnel plot as
suggested by Chaimani 2012. However, if we find any meaningful order, for example, the control group used depended upon the year
of conduct of the trial, we will use comparison-adjusted funnel plot as suggested by Chaimani 2012.
Data synthesis
Methods for indirect and mixed comparisons
We will conduct network meta-analyses to compare multiple interventions simultaneously for each of the primary and secondary
outcomes. Network meta-analysis combines direct evidence within trials and indirect evidence across trials (Mills 2012).We will obtain
a network plot to ensure that the trials were connected by treatments using Stata/SE 14.2 (Chaimani 2013). We will exclude any trials
that were not connected to the network. We will conduct a Bayesian network meta-analysis using the Markov chain Monte Carlo
method in OpenBUGS 3.2.3 as per the guidance from the National Institute for Health and Care Excellence (NICE) Decision Support
Unit (DSU) documents (Dias 2014a). We will model the treatment contrast (i.e. log odds ratio for binary outcomes, mean difference
or standardised mean difference for continuous outcomes, log rate ratio for count outcomes, and log hazard ratio for time-to-event
outcomes) for any two interventions (’functional parameters’) as a function of comparisons between each individual intervention and
an arbitrarily selected reference group (’basic parameters’) (Lu 2006) using appropriate likelihood functions and links. We will use
binomial likelihood and logit link for binary outcomes, Poisson likelihood and log link for count outcomes, binomial likelihood and
complementary log-log link for time-to-event outcomes, and normal likelihood and identity link for continuous outcomes. We will
perform a fixed-effect model and random-effects model for the network meta-analysis. We will report both models for comparison
54Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
with the reference group in a forest plot. For pair-wise comparison, we will report the fixed-effect model if the two models reported
similar results; otherwise, we will report the more conservative model.
We will use a hierarchical Bayesian model using three different initial values using codes provided by NICE DSU (Dias 2014a). We will
use a normal distribution with large variance (10,000) for treatment effect priors (vague or flat priors). For the random-effects model,
we will use a prior distributed uniformly (limits: 0 to 5) for between-trial standard deviation but assumed similar between-trial standard
deviation across treatment comparisons (Dias 2014a). We will use a ’burn-in’ of 5000 simulations, check for convergence visually,
and run the models for another 10,000 simulations to obtain effect estimates. If we did not obtain convergence, we will increase the
number of simulations for ’burn-in’. If we do not obtain convergence still, we will use alternate initial values and priors using methods
suggested by van Valkenhoef 2012. We will also estimate the probability that each intervention ranks at one of the possible positions
using the NICE DSU codes (Dias 2014a).
Assessment of inconsistency
We will assess inconsistency (statistical evidence of the violation of transitivity assumption) by fitting both an inconsistency model and
a consistency model. We will use the inconsistency models used in the NICEDSUmanual, as we plan to use a common between-study
deviation for the comparisons (Dias 2014b). In addition, we will use the design-by-treatment full interaction model (Higgins 2012)
and IF (inconsistency factor) plots (Chaimani 2013) to assess inconsistency. In the presence of inconsistency, we will assess whether the
inconsistency is because of clinical or methodological heterogeneity by performing separate analyses for each of the different subgroups
mentioned in the ’Subgroup analysis and investigation of heterogeneity for network meta-analysis’ section below.
If there is evidence of inconsistency, we will identify areas in the network where substantial inconsistency might be present in terms of
clinical and methodological diversities between trials and, when appropriate, limit network meta-analysis to a more compatible subset
of trials.
Direct comparison
We will perform the direct comparisons using the same codes and the same technical details.
Sample size calculations
To control for the risk of random errors, we will interpret the information with caution when the accrued sample size in the network
meta-analysis (i.e. across all treatment comparisons) was less than the required sample size (required information size). For calculation
of the required information size, see Appendix 3.
Subgroup analysis and investigation of heterogeneity for network meta-analysis
Wewill assess the differences in the effect estimates between the subgroups listed in ’Subgroup analysis and investigation of heterogeneity’
using meta-regression with the help of the OpenBUGS code (Dias 2012a) if we include a sufficient number of trials. We will use the
potential modifiers as study level covariates for meta-regression. We will calculate a single common interaction term (Dias 2012a). If
the 95% credible intervals of the interaction term do not overlap zero, we will consider this as evidence of difference in subgroups.
Presentation of results
We will present the effect estimates with 95% CrI for each pair-wise comparisons calculated from the direct comparisons and network
meta-analysis. We will also present the cumulative probability of the treatment ranks (i.e. the probability that the treatment is within
the top two, the probability that the treatment is within the top three, etc.) in graphs (surface under the cumulative ranking curve
or SUCRA) (Salanti 2011). We will also plot the probability that each treatment is best, second best, third best etc. for each of the
different outcomes (rankograms), which are generally considered more informative (Salanti 2011; Dias 2012b).
We will present the ’Summary of findings’ tables for mortality. In the ’Summary of findings for the main comparison’, we will follow
the approach suggested by Puhan and colleagues (Puhan 2014). First, we will calculate the direct and indirect effect estimates and 95%
credible intervals using the node-splitting approach (Dias 2010), i.e. calculate the direct estimate for each comparison by including
only trials in which there was direct comparison of treatments and the indirect estimate for each comparison by excluding the trials in
which there was direct comparison of treatments. Then we will rate the quality of direct and indirect effect estimates using GRADE
which takes into account the risk of bias, inconsistency, directness of evidence, imprecision, and publication bias (Guyatt 2011). Then,
we will present the estimates of the network meta-analysis and rate the quality of network meta-analysis effect estimates as the best
quality of evidence between the direct and indirect estimates (Puhan 2014). In addition, in the same table, we will present illustrations
and information on the number of trials and participants as per the standard ’Summary of Findings’ Table.
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Appendix 2. Search strategies
Database Time span Search strategy
The Central Register of Controlled Trials
(CENTRAL) (Wiley)
Issue 4,2016. #1 MeSH descriptor: [Hepatitis C] explode all trees
#2 “hepatitis C” or HCV
#3 #1 or #2
#4 acute
#5 #3 and #4
MEDLINE (OvidSP) January 1947 to April 2016. 1. exp hepatitis C/
2. (“hepatitis C” or HCV).ti,ab.
3. 1 or 2
4. acute.ti,ab.
5. 3 and 4
6. randomized controlled trial.pt.
7. controlled clinical trial.pt.
8. randomized.ab.
9. placebo.ab.
10. drug therapy.fs.
11. randomly.ab.
12. trial.ab.
13. groups.ab.
14. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15. exp animals/ not humans.sh.
16. 14 not 15
17. 5 and 16
Embase (OvidSP) January 1974 to April 2016. 1. exp hepatitis C/
2. (“hepatitis C” or HCV).ti,ab.
3. 1 or 2
4. acute.ti,ab.
5. 3 and 4
6. exp crossover-procedure/ or exp double-blind proce-
dure/ or exp randomized controlled trial/ or single-blind
procedure/
7. (((((random* or factorial* or crossover* or cross over*
or cross-over* or placebo* or double*) adj blind*) or sin-
gle*) adj blind*) or assign* or allocat* or volunteer*).af
8. 6 or 7
9. 5 and 8
Science Citation Index Expanded (Web of
Knowledge)
January 1945 to April 2016. #1 TS=(“hepatitis C” or HCV)
#2 TS=(acute)
#3 TS=(random* OR rct*OR crossoverORmaskedOR
blind* OR placebo* OR meta-analysis OR systematic
review* OR meta-analys*)
#4 #1 AND #2 AND #3
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(Continued)
World Health Organization International
Clini-
cal Trials Registry Platform Search Portal (
apps.who.int/trialsearch/Default.aspx)
April 2016. Condition: “acute hepatitis C”
ClinicalTrials.gov April 2016. Interventional Studies | “acute hepatitis C” | Phase 2, 3,
4
Appendix 3. Sample size calculation
The five-year mortality in people with chronic HCV infection is about 20% (Seeff 2001). The main aim of treatment for acute HCV
infection is to prevent its progress to chronic HCV infection and its complications. Approximately 20% of people with acute HCV
infection progress to chronic HCV infection (expert opinion). Based on this, we estimate the five-year mortality in people with acute
HCV infection to be 4% (20% proportion of acute HCV infection to chronic HCV infection × 20% five-year mortality rate in people
with chronic HCV infection). The required information size based on a control group proportion of 4%, a relative risk reduction of
20% in the intervention group, type I error of 5%, and type II error of 20% is 17,026 participants. Network analyses are more prone to
the risk of random errors than direct comparisons (Del Re 2013). Accordingly, a greater sample size is required in indirect comparisons
than direct comparisons (Thorlund 2012). The power and precision in indirect comparisons depend upon various factors, such as
the number of participants included under each comparison and the heterogeneity between the trials (Thorlund 2012). If there is no
heterogeneity across the trials, the sample size in indirect comparisons would be equivalent to the sample size in direct comparisons.
The effective indirect sample size can be calculated using the number of participants included in each direct comparison (Thorlund
2012). For example, a sample size of 2500 participants in the direct comparison A versus C (nAC) and a sample size of 7500 participants
in the direct comparison B versus C (nBC ) results in an effective indirect sample size of 1876 participants. However, in the presence
of heterogeneity within the comparisons, the sample size required is higher. In the above scenario, for an I2 statistic for each of the
comparisons A versus C (IAC
2) and B versus C (IBC
2) of 25%, the effective indirect sample size is 1407 participants. For an I2 statistic
for each of the comparisons A versus C and B versus C of 50%, the effective indirect sample size is 938 participants (Thorlund 2012).
If there were only three groups and the sample size in the trials is more than the required information size, we will calculate the effective
indirect sample size using the following generic formula (Thorlund 2012):
((nAC × (1 - IAC
2)) × (nBC × (1 - IBC
2))/((nAC × (1 - IAC
2)) + (nBC × (1 - IBC
2)).
There is currently no method to calculate the effective indirect sample size for a network analysis involving more than three intervention
groups.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• It was not possible to assess whether the potential effect modifiers were similar across different comparisons. Therefore, we did
not perform the network meta-analysis, and we assessed the comparative benefits and harms of different interventions using standard
Cochrane methodology. The methodology that we plan to use if we conduct a network meta-analysis in the future is available in
Appendix 1.
• We performed Trial Sequential Analysis in addition to conventional methods of assessing the risk of random errors using P values.
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N O T E S
Considerable overlap is evident in the ’Methods’ sections of this review and those of several other reviews written by the same group of
authors.
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